Verastem (VSTM)
(Delayed Data from NSDQ)
$3.27 USD
-0.20 (-5.76%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $3.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 141 - 160 ( 265 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Exploring Indications Beyond Duvelisib''s Initial Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
DUO Results at ASH Supportive of NDA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
PI3K Arbitrage; Initiating with Buy and $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Full DUO Results at ASH; Gearing Up for Duvelisib Approval in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Positive DUO Results Paves Way For 2018 Launch; New $10 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal DUO Study Expected to Report in 3Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal DUO Study to Report in Mid-2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
The Power of One: The Future of Personalized Cancer Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
DUO to Report in Mid-2017; Duvelisib Has Significant Commercial Potential; Reiterate Buy; Raising PT to $6.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
DYNAMO Serves Notice on Intractable Population; Docs Should Manage Safety
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Multiple Data Readouts in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; New Asset and Continuing "Watch and Wait"
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Calculated Play With a Long-Term View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
New Clinical Study Collaboration Provides More Shots on Goal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S